Kiniksa Pharmaceuticals Ltd Working Capital to Net Assets Ratio
Kiniksa Pharmaceuticals Ltd working capital to net assets ratio. Kiniksa Pharmaceuticals Ltd (KNSA) has a Working Capital to Net Assets ratio of 76.0% as of June 2026. Working capital of $497.39 Million (current assets of $668.63 Million minus current liabilities of $171.25 Million) is measured against net assets of $654.15 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Kiniksa Pharmaceuticals Ltd (2016–2025)
Working capital to net assets ratio of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. This chart shows how Kiniksa Pharmaceuticals Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 76.0%, reflecting working capital of $497.39 Million against net assets of $654.15 Million USD. See how many days can Kiniksa Pharmaceuticals Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Kiniksa Pharmaceuticals Ltd Working Capital to Net Assets Ratio by Year (2016–2025)
Kiniksa Pharmaceuticals Ltd working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Kiniksa Pharmaceuticals Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see KNSA asset base.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 68.4% | $387.99 Million | $567.61 Million | $527.18 Million | $139.18 Million | ▲ +15.6 pp |
| 2024 | 52.7% | $231.18 Million | $438.44 Million | $331.80 Million | $100.62 Million | ▲ +4.3 pp |
| 2023 | 48.5% | $212.63 Million | $438.84 Million | $276.30 Million | $63.67 Million | ▼ -1.0 pp |
| 2022 | 49.5% | $195.99 Million | $396.15 Million | $243.06 Million | $47.07 Million | ▼ -32.5 pp |
| 2021 | 81.9% | $151.62 Million | $185.04 Million | $196.45 Million | $44.82 Million | ▼ -14.7 pp |
| 2020 | 96.6% | $301.40 Million | $311.94 Million | $333.25 Million | $31.85 Million | ▲ +1.8 pp |
| 2019 | 94.8% | $213.80 Million | $225.42 Million | $241.63 Million | $27.83 Million | ▼ -2.3 pp |
| 2018 | 97.1% | $271.20 Million | $279.27 Million | $313.75 Million | $42.55 Million | ▲ +130.2 pp |
| 2017 | -33.1% | $29.67 Million | $-89.71 Million | $47.10 Million | $17.43 Million | ▲ +176.9 pp |
| 2016 | -210.0% | $54.03 Million | $-25.73 Million | $56.33 Million | $2.30 Million | — |